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Synthetic antimicrobial and LPS-
neutralising peptides suppress 
inflammatory and immune 
responses in skin cells and promote 
keratinocyte migration
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Günther Weindl1
The stagnation in the development of new antibiotics and the concomitant high increase of resistant 
bacteria emphasize the urgent need for new therapeutic options. Antimicrobial peptides are promising 
agents for the treatment of bacterial infections and recent studies indicate that Pep19-2.5, a synthetic 
anti-lipopolysaccharide (LPS) peptide (SALP), efficiently neutralises pathogenicity factors of Gram-
negative (LPS) and Gram-positive (lipoprotein/-peptide, LP) bacteria and protects against sepsis. 
Here, we investigated the potential of Pep19-2.5 and the structurally related compound Pep19-4LF for 
their therapeutic application in bacterial skin infections. SALPs inhibited LP-induced phosphorylation 
of NF-κB p65 and p38 MAPK and reduced cytokine release and gene expression in primary human 
keratinocytes and dermal fibroblasts. In LPS-stimulated human monocyte-derived dendritic cells and 
Langerhans-like cells, the peptides blocked IL-6 secretion, downregulated expression of maturation 
markers and inhibited dendritic cell migration. Both SALPs showed a low cytotoxicity in all investigated 
cell types. Furthermore, SALPs markedly promoted cell migration via EGFR transactivation and 
ERK1/2 phosphorylation and accelerated artificial wound closure in keratinocytes. Peptide-induced 
keratinocyte migration was mediated by purinergic receptors and metalloproteases. In contrast, SALPs 
did not affect proliferation of keratinocytes. Conclusively, our data suggest a novel therapeutic target 
for the treatment of patients with acute and chronic skin infections.
Owing to the alarming increase in bacterial resistance towards conventional antibiotics and the decrease in the 
development of new antibiotics at the same time, treatment of bacterial infections has become a major clinical 
problem1. This is particularly relevant for bacterial skin and soft-tissue infections (SSTIs) being most commonly 
caused by multidrug-resistant bacteria with Staphylococcus aureus as predominant causative Gram-positive bac-
terium and Pseudomonas aeruginosa as most frequent Gram-negative bacterium and having fatal consequences if 
treated unproperly2. Bacteria can release endotoxins like lipopolysaccharide (LPS) or other pathogenicity factors 
such as lipopoteins/peptides (LP) from their cell envelope, even due to treatment with conventional antibiotics, 
being able to activate Toll-like receptors (TLRs) and induce a strong inflammatory response. Synthetic anti-LPS 
peptides (SALPs) were specifically developed to neutralise these pathogenicity factors and represent an innovative 
approach for the treatment of bacterial sepsis3,4.
The skin comprises various cell types providing the potential to react to bacterial pathogenicity factors and 
can thus initiate inflammatory responses if exposed to these factors5. Keratinocytes are central sentinels of the 
skin endowed with the capability of recognising pathogen-associated molecular patterns and danger-associated 
molecular patterns via TLRs and the inflammasome machinery6. Furthermore, keratinocyte migration and 
proliferation are critical for re-epithelialization of skin wounds7. Fibroblasts residing in the dermis and thus 
being exposed to pathogens invading deeper layers of the skin are able to amplify cutaneous immune resonses 
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by secreting pro-inflammatory cytokines and chemokines in cross-talk with activated keratinocytes8,9. While 
keratinocytes are an important part of innate immunity, antigen presenting cells (APCs) are pivotal for initiation 
of adaptive immune responses and regulation of T cell responses10,11. Although inflammation is an important 
process to combat infections and to accelerate wound healing, overactivation of the immune system can lead to 
detrimental effects such as chronic skin inflammation12.
Recent evidence has suggested that endogenous and synthetic AMPs such as LL-37 and PXL150 may be ben-
eficial for the topical treatment of skin infections and wounds13–15. However, by acting on cell membranes their 
mode of antimicrobial action is rather non-specific with often poor selectivity for bacterial over mammalian 
cells16–19.
In this study, we investigated, if the SALP Pep19-2.5 and the structurally related compound Pep19-
4LF are likewise able to reduce inflammatory and immune responses evoked by the pathogenicity factors 
Fibroblast-stimulating lipopeptide-1 (FSL-1) for Gram-positive bacteria and LPS for Gram-negative bacteria in 
different skin cells. Additionally, we tested the ability of SALPs to modulate keratinocyte migration and prolif-
eration which are considered key events in wound healing during re-epithelialization. Our results demonstrate 
that synthetic anti-LPS peptides (SALPs) abrogate proinflammatory and immune responses in skin cells with 
the concomitant benefit of low cytotoxicity in all investigated cell types. Importantly, SALPs potently stimulate 
keratinocyte migration making them promising candidates for the treatment of acute and chronic bacterial skin 
infections.
Results
SALPs show low cytotoxicity in primary human keratinocytes and fibroblasts. AMPs may 
have cytotoxic effects on human keratinocytes even at low concentrations20. Pep19-2.5 and Pep19-4LF showed 
no effects on keratinocyte growth and viability for peptide concentrations up to 10 μ g/ml using the MTT assay 
(Fig. 1A). The IC50 values were 30 and 33 μ g/ml for Pep19-2.5 and Pep19-4LF, respectively. Additionally, peptide 
concentrations below 10 μ g/ml did not result in an increase of IL-8 secretion by keratinocytes (Fig. 1B) and 
annexin V/PI double positive cells (Fig. 1C). For primary human fibroblasts the MTT assay revealed IC50 values 
of 11 and 14 μ g/ml for Pep19-2.5 and Pep19-4LF, respectively (Fig. 1D). At peptide concentrations of 10 μ g/ml 
IL-8 secretion was increased (Fig. 1E). Thus, peptide concentrations of 1 μ g/ml were used for subsequent neutral-
isation experiments.
SALPs inhibit TLR2-induced responses in human keratinocytes and fibroblasts. Next, we inves-
tigated the capacity of the peptides to reduce TLR-induced cytokine production in primary human keratinocytes 
and in the human immortalised keratinocyte cell line HaCaT. In accordance with previous data indicating that 
keratinocytes and HaCaT cells failed to induce cytokines in response to TLR4 stimulation21, the TLR4 agonist 
LPS was not capable of provoking a significant increase of IL-8 secretion, not even in the presence of IFN-γ (data 
not shown). In contrast, primary human keratinocytes (Fig. 2A) and HaCaT cells (data not shown) responded 
Figure 1. Pep19-2.5 and Pep19-4LF show low cytotoxicity in primary human keratinocytes and fibroblasts. 
(A–C,E) Keratinocytes and (D,E) fibroblasts were stimulated for 24 h with different concentrations of Pep19-2.5 
and Pep19-4LF and analysed by cell viability assays. (A,D) Dose-response curves were obtained by MTT assay. 
Data are mean ± SD (n = 3-4). (B,E) IL-8 release into medium was quantified by ELISA. Data are mean + SD 
(n = 3-6). (C) Annexin V-FITC and PI staining followed by flow cytometry analysis. Double positive cells are 
displayed as fold change compared to control. Data are mean + SD (n = 3-4).
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Figure 2. SALPs protect against FSL-1-induced responses in keratinocytes and fibroblasts. (A–C) Keratinocytes, 
(D) HaCaT cells and (H) fibroblasts were stimulated with FSL-1 in the presence or absence of the peptides and 
additionally (D) only peptides in the absence of FSL-1. After 24 h, supernatants were collected and IL-8 secretion 
was quantified by ELISA. Data are mean + SD. (A) (n = 6-8). (B,C,H) (n = 3) * p ≤ 0.05, * * p ≤ 0.01, * * * * p ≤ 0.001, 
one-sample t test. (D) (n = 3). * * p ≤ 0.01, * * * * p ≤ 0.001, one-way ANOVA followed by Bonferroni posttest in 
comparison with FSL-1-treated cells in the absence of the peptides. (E) Primary keratinocytes were stimulated with 
0.01 or 0.1 μ g/ml FSL-1 in the presence or absence of 1 μ g/ml Pep19-2.5 or Pep19-4LF for 4 h and gene expression of 
IL1A, IL1B, MCP1 and hBD2 was determined by qPCR. mRNA expression values were normalised to YWHAZ. Data 
are mean + SD (n = 3). * p ≤ 0.05, * * p ≤ 0.01, one-sample t test. (B,E,H) Data were normalised to FSL-1-treated cells 
in the absence of the peptides (100%). (F) Keratinocytes were stimulated with FSL-1 (0. 01 μ g/ml) in the presence or 
absence of the peptides (1 μ g/ml) or with peptides alone (1 μ g/ml) for 30 min and phospho-p38 MAPK and phospho-
NF-κ B p65 were detected by Western blot analysis. Pictures are representative of three independent experiments.  
(G) Bar graphs obtained by densitometric analysis of western blot data. Mean + SD (n = 3). * p ≤ 0.05, one-way 
ANOVA followed by Bonferroni posttest.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:31577 | DOI: 10.1038/srep31577
to the TLR2/6 agonist FSL-1 by increased IL-8 production. IL-6 protein levels were almost not detectable after 
stimulation with FSL-1 in primary human keratinocytes (data not shown).
Both peptides significantly reduced FSL-1-induced IL-8 production in primary human keratinocytes at a 
peptide:FSL-1-ratio of 10:1 and IL-8 secretion was nearly completely abolished at a ratio of 100:1 (Fig. 2B). We 
also investigated the combined application of Pep19-2.5 and Pep19-4LF revealing no synergistic effect. The same 
experiments performed with a control peptide (Pep19-2.5gek) did not show any decrease of IL-8 secretion com-
pared to FSL-1 alone (Fig. 2C).
In HaCaT cells, the peptides alone did not increase IL-8 levels compared to control (Fig. 2D). We observed 
a significant reduction of FSL-1-induced IL-8 secretion when Pep19-2.5 was added at a ratio of 1:1 and for both 
peptides at a Pep:FSL-1-ratio of 100:1. For a Pep:FSL-1-ratio of 10:1 both peptides were not capable of attenuating 
the inflammatory effect of FSL-1.
AMPs are known to activate the inflammasome and there is increasing evidence that the inflammasome is like-
wise involved in IL-1α secretion22. However, IL-1α secretion was hardly detectable in FSL-1 stimulated cells and 
not regulated by the peptides (data not shown). In contrast, IL-1A and IL-1B mRNA levels were upregulated after 
4 h stimulation with FSL-1 while expression of both genes was downregulated in the presence of the peptides for a 
Pep:FSL-1 ratio of 100:1 being significant for both peptides for IL-1B but not IL-1A (Fig. 2E). Similarly, IL-18 secre-
tion is activated via the inflammasome machinery, however, we did not observe upregulated gene levels with FSL-1 
in the presence or absence of the peptides (data not shown). Furthermore, both peptides reduced gene expression 
of monocyte chemoattractant protein 1 (MCP1) significantly at a Pep:FSL-1-ratio of 100:1 whereas for Pep19-2.5 
a Pep:FSL-1-ratio of 10:1 was already sufficient to decrease MCP1 gene expression significantly (Fig. 2E). We also 
examined the gene regulation of the antimicrobial peptides hBD2 and hBD3. Notably, for a significant downregu-
lation of the hBD2 gene for both peptides already a Pep:FSL-1-ratio of 10:1 was sufficient (Fig. 2E) whereas hBD3 
gene expression was not significantly increased after stimulation with FSL-1 (data not shown).
As proinflammatory cytokines are regulated through NF-κ B and MAPK pathways and TLR2 signalling 
results in activation of the transcription factors23 we further investigated the phosphorylation of NF-κ B p65 and 
p38 MAPK with Western Blot. In fact, stimulation with FSL-1 induced phosphorylation of NF-κ B p65 and p38 
MAPK whereas addition of the peptides markedly suppressed their phosphorylation (Fig. 2F) being significant 
for Phospho-NF-κ B p65 after addition of Pep19-2.5 (Fig. 2G). The peptides alone had little effect on p65 and p38 
phosphorylation.
Skin infections can also expand to deeper layers of the skin. Fibroblasts as major cells of the dermal layer 
can participate in inflammatory processes and react to TLR2 but not TLR4 agonists9. However, none of the 
peptides was able to reduce FSL-1-induced IL-8 secretion culturing the fibroblasts in DMEM as basal medium 
(data not shown). When the cells were cultured in RPMI Pep19-2.5 reduced FSL-1-induced IL-8 secretion signif-
icantly for a Pep:FSL-1-ratio of 100:1 while Pep19-4LF remained inactive (Fig. 2H).
SALPs do not affect cell viability of cutanous dendritic cells and inhibit LPS-induced cytokine release. 
To determine if SALPs also neutralise LPS-induced responses in skin cells, we investigated monocyte-derived 
dendritic cells (MoDCs) and monocyte-derived Langerhans-like cells (MoLCs). Both peptides showed no apop-
totic or necrotic effect for concentrations up to 30 μ g/ml or even a lower amount of apoptotic/necrotic cells com-
pared to the untreated control (Fig. 3A–D). For MoDCs, LPS concentrations as low as 1 ng/ml resulted in a 
high increase of the pro-inflammatory cytokine IL-6, while IL12p70-levels were solely upregulated in four of six 
donors (data not shown). Notably, both peptides inhibited LPS dependent IL-6 production significantly when 
added at a Pep:LPS-ratio of 100:1 and almost completely at a Pep:LPS-ratio of 1000:1 (Fig. 4A). Pep19-2.5gek 
showed a slight reduction for a Pep:LPS-ratio of 1000:1 (Fig. 4B) likely due to rather unspecific binding to LPS 
(unpublished results). Also IL12p70 was strongly decreased in donors showing LPS-induced upregulation of this 
cytokine (data not shown).
MoLCs respond weakly to TLR2 activation and are only responsive toward LPS under inflammatory 
conditions24. Thus, we stimulated MoLCs additionally to LPS with the proinflammatory cytokines TNF and IL-1β . 
Addition of the peptides resulted in a decrease of IL-6 levels at a Pep:LPS-ratio of 10:1 (Fig. 4C) although this 
difference failed to be significant presumably owing to the supplementary stimulation with proinflammatory 
cytokines24. No decrease of IL-6 levels was observed after addition of the control peptide Pep19-2.5gek (Fig. 4D).
LPS-induced maturation and CCR7-dependent migration of dendritic cells is reduced by SALPs. 
To potently activate T cells, DCs undergo a maturation process resulting in upregulation of maturation 
markers and costimulatory molecules25. Stimulation of MoDCs with 1 and 10 ng/ml LPS resulted in almost 
the same amount of CD83 and CD86 double positive cells and for a Pep19-2.5:LPS-ratio of 1000:1 a signifi-
cant downregulation of the maturation markers could be achieved (Fig. 4E,F). The same applies to Pep19-4LF 
(data not shown). In MoLCs, the LPS-induced upregulation of the maturation markers was slightly reduced by 
Pep19-2.5 and Pep19-4LF for a Pep:LPS-ratio of 10:1 (data not shown).
Since activation of DCs does not necessarily correlate with their migratory capability26, we determined the 
expression of the chemokine CCR7 enabling them to migrate from the periphery to secondary lymphoid organs10. 
In MoDCs, LPS-induced CCR7 upregulation was decreased in the presence of Pep19-2.5 at a Pep:LPS-ratio of 
100:1 and significantly at a Pep:LPS-ratio of 1000:1 (Fig. 4G). Additionally, we evaluated the migratory capacity of 
LPS-stimulated MoDCs towards the chemoattractant CCL21. Stimulation with LPS resulted in a high migratory 
capacity of MoDCs along the CCL21 gradient which was completely blocked by Pep19-2.5 (Fig. 4H).
SALPs potently stimulate migration but not proliferation of human keratinocytes. In addition 
to acute inflammation, bacterial infections often result in impaired wound healing27. Since reepithelialization is 
a critical step in wound repair7, we tested the ability of Pep19-2.5 to stimulate the migratory activity of primary 
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human keratinocytes in the scratch wound assay. Remarkably, peptide concentrations as low as 1 ng/ml were 
able to markedly promote keratinocyte migration and accelerated artificial wound closure being even compa-
rable to TGF-β 1 (Fig. 5A), while higher concentrations were capable of completely closing the pseudo-“wound” 
with 1 μ g/ml as optimal concentration. Since it is well known that EGFR transactivation contributes to kerat-
inocyte migration28, we investigated the capacity of Pep19-2.5 to activate EGFR and EGFR-dependent extra-
cellular signal regulated kinase 1/2 (ERK1/2) signalling. Therefore, primary human keratinocytes were 
stimulated with different Pep19-2.5 concentrations resulting in a dose-dependent increase in EGFR- and 
ERK1/2-phosphorylation (Fig. 5B). The antimicrobial peptides LL-37 and melittin provoke EGFR transactivation 
via metalloprotease-mediated shedding of membrane-anchored EGFR ligands29,30. Thus, we analysed whether 
Pep19-2.5 induces EGFR-mediated phosphorylation of ERK1/2 via metalloprotease activation. In fact, Pep19-
2.5-induced phosphorylation of ERK1/2 was completely abolished in the presence of the EGFR tyrosine kinase 
inhibitor AG1478 and the broad-spectrum metalloproteinase inhibitor marimastat (Fig. 5B,C).
To confirm that the peptide-induced keratinocyte migration is due to metalloprotease-mediated EGFR 
transactivation, we additionally performed wound scratch assays with HaCaT cells in the presence or absence 
of AG1478 and marimastat. Since previous investigations with skin-derived peptides like SPINK9 revealed that 
purinergic receptors are involved in EGFR-transactivation31, we additionally used the unspecific inhibitor of 
purinergic receptors, PPADS. Similar to primary keratinocytes, Pep19-2.5 stimulated also HaCaT cell migration 
already at concentrations as low as 1 ng/ml and showed a dose-dependent increase with a maximal effect for 1 μ 
g/ml which was blocked by AG1478, marimastat and PPADS (Fig. 6A). In HaCaT cells we further investigated 
the effect of Pep19-4LF and the control peptide, Pep19-2.5gek, on keratinocyte migration revealing a comparable 
effect for Pep19-4LF to Pep19-2.5 at a concentration of 1 μ g/ml that could also be blocked by AG1478. In contrast, 
Pep19-2.5gek did not promote migration of HaCaT cells (Fig. 6A).
As wound closure is not exclusively due to cell migration, but also involves cell proliferation7, cells were pre-
treated with mitomycin c to exclude a potentially proliferative effect of the peptides. Furthermore, both pep-
tides showed no or little effect on cell proliferation of HaCaT cells up to 1 μ g/ml (Fig. 6B) implying that the 
peptide-mediated artificial wound closure is due to keratinocyte migration rather than proliferation.
Figure 3. No cytotoxicity observed in antigen-presenting cells for peptide concentrations as high as 30 μg/ml. 
(A,C) MoDCs and (B,D) MoLCs were stimulated with Pep19-2.5 and Pep19-4LF for 24 h. Annexin V-FITC and PI 
staining was performed followed by flow cytometry analysis. (A,B) Dot Plots from the same donor are representative 
for 3 independent experiments and percentage of stained cells is indicated. Staurosporine (1 μ M) served as positive 
control. (C,D) Annexin V-positive cells are displayed as fold change compared to control. Data are mean + SD (n = 3).
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Discussion
In this study, we show that synthetic anti-LPS peptides (SALPs) abrogate TLR-induced responses in different 
skin cells with low cytotoxic effects. Given the importance of keratinocytes for early cutaneous innate immune 
responses32, the strong FSL-1-neutralising effect of Pep19-2.5 and Pep19-4LF provides a major contribution to 
prevent activation of the cutaneous immune system. SALPs might have the capability to inhibit the first inflam-
matory response after recognition of pathogens since they reduce the FSL-1-induced secretion of chemokines in 
keratinocytes. With the reduction of IL-8 they contribute to the inhibition of neutrophil recruitment to the site of 
infection6, whereas MCP-1 downregulation might attenuate monocyte infiltration33. This is further supported by 
the downregulation of the AMP hBD-2 whose secretion is upregulated in skin infections to support chemotaxis 
and secretion of proinflammatory cytokines34. As the peptides also reduce the concomitant upregulation of the 
proinflammatory cytokines IL-1α and IL-1β they may inhibit the subsequent activation of skin-resident immune 
cells that are capable to maintain and promote the ongoing immune response6.
The peptides showed a lower antiinflammatory effect but higher cytotoxicity in dermal fibroblasts compared 
to keratinocytes. The use of D-amino acid peptides revealed no further decrease of IL-8 secretion indicating that 
Figure 4. SALPs inhibit LPS-induced cytokine secretion, maturation and CCR7-dependent migration of 
dendritic cells. (A,B) MoDCs were stimulated with 1 or 10 ng/ml LPS (MoDCs) and (C,D) MoLCs with 100 ng/ml 
LPS together with 20 ng/ml TNF and 10 ng/ml IL-1β in the presence or absence of the peptides (1 μ g/ml) for 24 h, 
supernatants were collected and IL-6 production was quantified by ELISA. Data are mean + SD (n = 3-8).  
* p ≤ 0.05, * * p ≤ 0.01, * * * p ≤ 0.001, one-sample t test. (E) MoDCs were stimulated with 1 or 10 ng/ml LPS in the 
presence or absence of Pep19-2.5 (1 μ g/ml) for 24 h and surface expression of CD83 and CD86 was analysed by 
two-colour flow cytometry. Dot Plots are representative for 3 independent experiments and percentage of stained 
cells is indicated. (F) Bar chart summarizes means of double-positive cells. Mean + SD (n = 3). * * * p ≤ 0.001, one-
sample t test. (G) MoDCs were stimulated with 10 ng/ml LPS in the presence or absence of Pep19-2.5 for 24 h and 
gene expression of CCR7 was analysed by qPCR. mRNA expression values were normalised to YWHAZ. Data are 
mean + SD (n = 3). * p ≤ 0.05, one-sample t test. (A,C,G) Data were normalised to LPS-treated cells in the absence 
of the peptides (100%). (H) MoDCs were stimulated with 1 ng/ml LPS in the presence or absence of Pep19-2.5 for 
48 h. Cell migration was evaluated after 2.5 h towards the ligand CCL21 (100 ng/ml) by flow cytometry. Data are 
mean + SD (n = 4).
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proteolytic degradation is not involved (data not shown). Although the culture medium composition affected the 
activity of Pep19-2.5, the underlying mechanisms remain unclear. Since we could demonstrate an involvement of 
Pep19-2.5 in EGFR transactivation and a role of this receptor in TLR2-mediated inflammation has been noted35, 
we assumed a possibly influence of the peptides on EGFR-induced inflammatory responses that could counter-
act the neutralising and thus anti-inflammatory effect in fibroblasts. However, IL-8 levels remained unchanged 
in fibroblasts in the presence of the EGFR tyrosine kinase inhibitor AG1478 (data not shown) suggesting no 
cross-talk between EGFR and TLR2 signalling pathways.
SALPs are further capable of inhibiting LPS-induced activation of dendritic cells, similarly to LL-3736. Since 
MoLCs are only responsive to TLR4 agonists under inflammatory conditions24 and SALPs suppress inflamma-
tory responses in keratinocytes, LC activation might be limited in the presence of SALPs. Reduced maturation 
and migration of DCs results in decreased T cell activation and proliferation36. Consequently, detrimental local 
inflammatory reactions during S. aureus skin infections37 or the development of chronic inflammation dominated 
by a delayed lymphocyte response would seem less likely12.
Interestingly, the cytotoxicity of SALPs is considerably lower in MoDCs and MoLCs compared to keratino-
cytes and fibroblasts. Previous studies with LL-37 indicate that this AMP is able to suppress neutrophil apoptosis 
via activation of formyl-peptide receptor-like 1 (FPRL1) and P2X7R receptor38. It would be interesting to deter-
mine whether these receptors are involved in the protective effect of SALPs in cutaneous dendritic cells.
Synthetic mimics of antimicrobial peptides are able to reduce the production of proinflammatory cytokines in 
response to LTA, but not to other TLR2 agonists or LPS39. In contrast, SALPs are able to neutralise pathogenicity 
factors of both Gram-positive and Gram-negative bacteria giving them a broad-spectrum activity. Pep19-2.5 
binds with high affinity to LPS from Gram-negative bacteria3,4 and to corresponding LP from Gram-positive 
bacteria or Mycoplasma40. Isothermal titration calorimetry revealed a strong exothermic reaction with saturation 
characteristics between Pep19-2.5 and LPS or LP, respectively. This interaction is connected, as has been proven 
Figure 5. Pep19-2.5 promotes migration of primary human keratinocytes and metalloprotease/EGFR-
dependent ERK1/2 activation. (A) Keratinocytes were scratched and stimulated with Pep19-2.5. TGF-β 1 (1 ng/ml) 
served as positive control. Images were taken directly after scratching (0 h) and after 17 h and are representative of 
three independent experiments. (B,C) Keratinocytes were pretreated with marimastat (10 μ M) or AG1478 (50 nM) 
and subsequently stimulated with Pep19-2.5 for 15 min. DMSO (0.1%, v/v) was used as solvent control. Expression 
of phospho-EGFR and phospho-ERK1/2 was detected by Western blot analysis. (B) Blots are representative of 
three independent experiments. (C) Bar graphs obtained by densitometric analysis of western blot data. Data are 
normalised to control (assigned as 1.0). Mean + SD (n = 3).
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Figure 6. Peptide-induced keratinocyte migration depends on purinergic receptors and metalloproteases. 
(A) HaCaT cells were scratched and stimulated with Pep19-2.5 in the presence or absence of the inhibitors 
AG1478 (50 nM), marimastat (10 μ M) and PPADS (50 μ M). TGF-β 1 served as positive control. Images were 
taken directly after scratching (0 h) and after 20 h and are representative of three independent experiments. 
(B) HaCaT cells were stimulated with Pep19-2.5 and Pep19-4LF in the presence or absence of the inhibitors 
AG1478 (50 nM), marimastat (10 μ M) and PPADS (50 μ M). After 24 h EdU incorporation was quantified. Data 
are normalised to unstimulated cells (assigned as 1.0). Cells incubated with growth medium served as positive 
control. Data are mean + SD (n = 3).
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for LPS41, with a conversion of the aggregate structure of the pathogenicity factors into a bioinactive multilamellar 
arrangement, which cannot be recognised by the corresponding cell surface receptors TLR2 and TLR4. A sim-
ilar mode of action can be expected for Pep19-4LF. Most studies regarding antimicrobial peptides address their 
antibacterial effect affecting bacterial membranes and killing bacteria due to membrane-lytic processes42. Owing 
to the diversity of different bacteria it appears to be challenging to achieve a broad-spectrum activity with these 
AMPs. In contrast, SALPs target structures that are constituents of all bacteria species and could thus broaden the 
field of therapeutic application.
The strong antiinflammatory effect of SALPs - both in keratinocytes and antigen-presenting cells of the skin - 
makes them potential candidates for the treatment of skin and soft-tissue infections (SSTIs) or rather for the 
prevention of complicated SSTIs (cSSTIs). As SSTIs are the third most frequent cause for severe sepsis and sep-
tic shock43, making less complicated SSTIs to cSSTIs, proper treatment of these infections is indispensable. Of 
particular interest are infections caused by S. aureus becoming increasingly resistant especially towards topical 
antibiotics like mupirocin and fusidic acid13. Since AMPs target highly conserved structures of bacteria the prob-
ability of resistance development is rather unlikely17. Thus, SALPs could be a promising option for the treatment 
of infections with multiresistant bacteria, preferably in combination with antibacterial agents or other AMPs 
with strong antimicrobial activities, due to the low antimicrobial effect of Pep19-2.54. Alternatively, a combi-
nation of Pep19-2.5 and Pep19-4LF could be considered giving a stronger antimicrobial activity of the latter 
SALP against Gram-negative and Gram-positive bacteria (own unpublished data), but a less inhibitory effect 
of the LPS-induced cytokine response in mononuclear cells44. In keratinocytes and dendritic cells, however, we 
observed a comparable pathogenicity factor neutralising effect for both SALPs. A key advantage of SALPs in 
this context is their ability to neutralise pathogenicity factors that can be released from bacterial envelopes after 
treatment with conventional antibiotics or simply due to the activation of the immune system4,45. Previous studies 
already show a synergistic effect of Pep19-2.5 with streptomycin for the reduction of LPS-induced TNF secre-
tion46. Further studies are planned to investigate the effect of SALPs in skin infection models in combination with 
conventional antibiotics.
As bacterial skin infections are often associated with impaired wound healing additional wound healing prop-
erties would give a higher significance to compounds used for their treatment. Our study reveals that SALPs are 
effectively able to induce keratinocyte migration via EGFR transactivation, hence supporting re-epithelilization, 
a critical step in the wound healing process7. Importantly, SALPs seem far superior to LL-37 or melittin which 
accelerate wound closure only at much higher concentrations28,30. The Pep19-2.5-induced keratinocyte migra-
tion can be explained by the activation of metalloproteases followed by shedding of EGFR ligands and subse-
quent activation of EGFR which is also in accordance with previous data for the skin-derived peptide SPINK931. 
Studies with melittin and SPINK9 point out that purinergic receptors are involved in the activation of metallo-
proteases30,31. Indeed, PPADS was able to decrease Pep19-2.5-induced keratinocyte migration indicating that 
Pep19-2.5-induced EGFR transactivation might also be due to purinergic receptor activation. Additional studies 
are required to characterize a possible direct interaction between purinergic receptors and SALPs.
In this study, we show that SALPs reduce the inflammatory and immune response in skin cells stimulated 
with potent bacterial pathogenicity factors with concurrent potent stimulation of keratinocyte migration and low 
cytotoxicity. Since bacterial endotoxins can give rise to prolonged increase of proinflammatory cytokines leading 
to chronic wound infections47, SALPs additionally might be a promising option for the treatment of acute and 
chronic wounds most commonly infected with S. aureus and P. aeruginosa48.
Methods
Cell culture. All donor and patient samples were obtained after written informed consent and only 
anonymised samples were used for the experiments. All experiments were performed in accordance with rele-
vant guidelines and regulations and were approved by the ethics committee of the Charité - Universitätsmedizin 
Berlin, Germany. For primary cultures, normal human epidermal keratinocytes and dermal fibroblasts were iso-
lated from human juvenile foreskin and cultured as described with minor modifications49,50. Keratinocytes were 
grown in keratinocyte basal medium (KBM; Lonza, Basel, Switzerland) supplemented with insulin, hydrocor-
tisone, human epidermal growth factor and bovine pituitary extract (keratinocyte growth medium; KGM) as 
provided by the manufacturer. Fibroblasts and the immortalised keratinocyte cell line HaCaT (CLS Cell Lines 
Service, Eppelheim, Germany) were cultured in RPMI-1640 (Sigma-Aldrich, Taufkirchen, Germany) containing 
2 mM l-glutamine, 100 U/ml penicillin, 100 μ g/ml streptomycin (all from PAA Laboratories, Pasching, Austria) 
and 10% (v/v) fetal calf serum (Biochrom, Berlin, Germany). MoLCs and MoDCs were differentiated from 
human monocytes as previously described24,51,52.
Peptide synthesis. Pep19-2.5gek and Pep19-4LF were synthesised at the Borstel Research Institute with an 
amidated C terminus by the solid-phase peptide synthesis technique in an automatic peptide synthesizer (model 
433A; Applied Biosystems) on Fmoc-Rink amide resin, according to the 0.1-mmol FastMoc synthesis protocol of 
the manufacturer, including the removal of the N-terminal Fmoc group. Further details are described elsewhere3. 
Peptide 19-2.5, also termed Aspidasept®, was purchased from Bachem (Bubendorf, Switzerland) as research 
grade compound. The purity of all peptides was better than 95% as determined by HPLC and mass spectrometry. 
The sequences are as follows: Pep19-2.5, GCKKYRRFRWKFKGKFWFWG; Pep19-2,5gek, a shortened variant of 
Pep19-2.5, GCKKYRRFRWKFKGK; Pep19-4LF: GKKYRRFRWKFKGKLFLFG. The sequences of the peptides 
are protected in an international patent, which was granted by the European Patent Office (patent 2108 372 A1) 
in 2015 for EU, USA, and Japan.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:31577 | DOI: 10.1038/srep31577
Cell stimulation. Primary cells from the 3rd passage were used and pooled from at least three donors 
to reduce donor-specific properties. Before stimulation, fibroblasts and HaCaT cells were washed with 
phosphate-buffered saline (PBS; Sigma-Aldrich) and basal medium without FCS and antibiotics was added for 
24 h. In the migration studies with primary keratinocytes, KGM was changed to KBM to exclude effects of added 
growth factors in the cell culture medium.
Fibroblast-stimulating lipopeptide-1 (FSL-1, EMC Microcollections, Tübingen, Germany) and lipopolysac-
charide (LPS) from Salmonella enterica Minnesota R604 with or without 20 ng/ml IFN-γ (Peprotech, Hamburg, 
Germany) were used as TLR2 and TLR4 agonists, respectively. The peptides were preincubated with the respec-
tive stimuli for 30 min before addition to the cells. MoLCs were stimulated with LPS in the presence of 20 ng/ml 
TNF (eBioscience, San Diego, USA) and 10 ng/ml IL-1β (BioLegend, San Diego, USA).
Cell viability and proliferation. Cytotoxicity was determined by the MTT assay in keratinocytes and 
fibroblasts20. Viability of untreated cells was set at 100%. IC50 values were calculated using GraphPad Prism 6.0 
(San Diego, USA). In addition, cell death was measured by annexin V-FITC (BioLegend, San Diego, USA) and 
propidium iodide (PI) (Sigma-Aldrich) double staining. Cells were examined using the Cytoflex flow cytometer 
(Beckman Coulter, Krefeld, Germany) collecting a total of 1-2 × 104 events. PI (1 μ g/ml) was added to the samples 
directly before analysis. Staurosporine (1 μ M; Tocris, Bristol, UK) served as positive control.
Proliferation of HaCaT cells was determined with EdU HTS Kit 488 (Sigma-Aldrich) according to the manu-
facturer’s instructions. Briefly, after 24 h stimulation cells were incubated with 10 μ M 5-ethynyl-2′ -deoxyuridine 
(EdU), fixed and permeabilised and after addition of a fluorescent dye (6-FAM Azide) EdU incorporation was 
determined by quantification of fluorescence intensity (FLUOstar Optima, BMG Labtech, Offenburg, Germany) 
(excitation: 485 nm; emission: 520 nm). All experiments were performed in triplicate.
Flow cytometry. The cell surface expression of CD83 and CD86 was analysed in MoDCs and MoLCs by 
two-colour flow cytometry as described24.
In vitro scratch assay. The scratch assay was performed as described before with minor modifications9. 
Briefly, keratinocytes and HaCaT cells were seeded in 6-well plates (TPP) and grown until they reached con-
fluence. Cells were pretreated for 2 h with 5 μ g/ml mitomycin C (Tocris) to prevent cell proliferation. After this 
a cell-free area was introduced by scraping the monolayer with a sterile 200-μ l pipette tip. Cells were washed 
twice with PBS and the medium was changed to basal medium. The peptides were added in the absence or pres-
ence of the broad-spectrum metalloprotease inhibitor marimastat (MM; 10 μ M; Sigma-Aldrich), the epidermal 
growth factor tyrosine kinase inhibitor AG1478 (50 nM; Tocris) or the non-selective P2 purinergic antagonist 
Pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid tetrasodium salt (PPADS; 50 μ M; Sigma-Aldrich). TGF-β 1 
(1 ng/ml, Miltenyi Biotech) served as positive control. Scratches were documented under a microscope with 10x 
(keratinocytes) or 5x (HaCaT cells) magnification (Axiovert 135; Carl Zeiss, Jena, Germany) equipped with a 
digital SLR camera (Canon EOS 1000D; Canon Germany, Krefeld, Germany) immediately after the scratching 
procedure and once more when kept at 37 °C and 5% CO2 for 17 h for primary keratinocytes and 20 h for HaCaT 
cells. Pictures were taken exactly at the same position before and after the incubation to document the repair 
process. The experiments were repeated two times and representative pictures are shown.
Western blotting. After preincubation for 1 h with AG1478 (50 nM; Sigma-Aldrich) or MM (10 μ M; Tocris) 
keratinocytes were stimulated for 15 or 30 min for detection of Phospho-EGFR and Phospho-ERK1/2 or 
Phospho-NF-κ B p65 and Phospho-p38 MAPK, respectively. Subsequently, cells were lysed and prepared as 
described previously9,52. After gel electrophoresis and blotting membranes were blocked with 5% bovine serum 
albumin (BSA; Sigma-Aldrich) for 1 h at 37 °C, membranes were incubated with anti-Phospho-NF-κ B p65 
(Ser 536) Antibody (1:1000), anti-Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP Rabbit mAb (1:1000), 
anti-Phospho-EGFR (Tyr1068) (D7A5) XP Rabbit mAb (1:1000) or anti-Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (D13.14.4E) XP Rabbit mAb (1:1000) (all from NEB, Germany) over night at 4 °C and incubated 
with anti-rabbit horseradish-peroxidase (HRP)-conjugated secondary antibody (NEB; 1:1000) for 1 h. Then blots 
were developed with SignalFire ECL reagent (NEB) and visualised by PXi Touch gel imaging system (Syngene, UK). 
The membranes were stripped with Restore Western Blot Stripping Buffer (Thermo Scientific) and further rep-
robed with anti-β -actin rabbit antibody (clone 13E5, 1:1000, NEB), anti-p38 MAPK (D13E1) XP Rabbit mAb, 
anti-EGFR (D38B1) XP Rabbit mAb or anti-p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (all 1:1000; NEB) to 
confirm comparable protein loading. Values of protein expression were measured by densitometry and normal-
ised to β -actin-, p38 MAPK-, EGFR- or p44/42 MAPK-levels using ImageJ version 1.46r.
ELISA. After 24 h of stimulation, cell culture media were assayed for IL-8, IL-6, IL-1α or IL-12p70 by using 
commercially available ELISA kits (ELISA-Ready Set Go; eBioscience).
RNA isolation, cDNA synthesis and quantitative RT-PCR. Total RNA isolation, cDNA synthesis 
and quantitative RT-PCR (qPCR) were performed as described previously49. The following primers (synthesised 
by TIB Molbiol, Germany) were used: YWHAZ53, CCR7, hBD2 and hBD354 and IL-1α and IL-1β9 as published 
previously; MCP-1, 5′-CATTGTGGCCAAGGAGATCTG-3′ and 5′-CTTCGGAGTTTGGGTTTGCTT-3′ and 
IL-18, 5′-TGCCAACTCTGGCTGCTAAA-3′ and 5′-TTGTTGCGAGAGGAAGCGAT-3′ . Fold difference in 
gene expression was normalised to the housekeeping gene YWHAZ which showed the most constant level of 
expression.
In vitro migration assay. To analyse CCR7-dependent migration MoDCs were harvested, washed two 
times in PBS and stimulated with LPS in the presence or absence of Pep19-2.5 for 48 h, as described above. 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:31577 | DOI: 10.1038/srep31577
After washing, 5 × 105 cells were added to the upper well of a 24-well transwell plate with 5 μ m pore size (BD 
Bioscience). Complete medium in the lower well was supplemented with rh-CCL21 (100 ng/ml; Miltenyi Biotech). 
MoDCs were allowed to migrate for 2.5 h. The migrated cells were harvested and counted in a FACSCalibur flow 
cytometer for 130 s. Cell debris was excluded by scatter gates.
Statistical analysis. Data are depicted as means + SD. Statistical significance of differences was determined 
by one-sample t test or one-way analysis of variance (ANOVA) followed by Bonferroni post-hoc analysis and con-
sidered significant at p ≤ 0.05. Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad software, 
San Diego, USA).
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